Gwo Xi Stem Cell Applied Technology Co., Ltd.

Gwo Xi Stem Cell Applied Technology Co., Ltd. is a biotechnology company specializing in the development of advanced stem cell therapies targeting complex, unmet medical needs. The company's primary focus is on creating innovative treatments using both autologous and allogeneic adipose-derived stem cells for a range of diseases, including liver cirrhosis, chronic stroke, osteoarthritis, and diabetes. Several of its flagship therapeutics, such as GXHPC1 and GXNPC1, have reached phase II and III clinical trials, evidencing its commitment to rigorous clinical development. In addition to stem cell medicines, Gwo Xi pioneers mesenchymal stem cell-derived exosome technologies, which have found applications in cosmetics and regenerative medicine. With integrated PIC/S GMP-grade facilities and a comprehensive CDMO/CMO service offering, the company serves as a key player in the global supply chain for regenerative therapies and supports collaborative innovation with academic, pharmaceutical, and cosmetic partners. Founded in 2011 and headquartered in Zhubei, Taiwan, Gwo Xi continues to shape the landscape of cell-based therapeutics and medical biotechnology in Asia and beyond.